Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
Status:
Completed
Trial end date:
2017-10-26
Target enrollment:
Participant gender:
Summary
The proposed study will carefully test the hypothesis that a robust dose of baclofen (90
mg/day) has efficacy and is safe in individuals with alcohol dependence. Furthermore, the
proposal will test whether an indicator of physical dependence, i.e. drinks/drinking day,
predicts response to baclofen. Additionally, the proposal will examine the anti-anxiety
effects of baclofen within an alcohol dependent population and ascertain whether baseline
levels of anxiety predict response to baclofen.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)